MetaVia Stock Slips Again Before a Big Obesity-Drug Week
MetaVia Inc. shares slipped before the bell on Thursday, extending a sharp pullback from last week’s rally as investors weighed early obesity-drug data against financing and listing risks at the small biotech. The Nasdaq-listed stock was quoted at $2.65 in pre-market trade, down 1.1%, after a $2.68 close on Wednesday. It has now retreated from $3.34 on May 27, the day MetaVia presented new Phase 1 data for DA-1726 at the European Association for the Study of the Liver Congress.